CRISPR Therapeutics AG (CRSP)
The price, the headline numbers and the latest news, in one place.
CRISPR Therapeutics AG (CRSP) Stock Price, Analysis & Data
| Bid | 44.5 |
| Market Cap | 5.39B |
| Revenue (ttm) | 13.4M |
| Net Income (ttm) | -451M |
| 1.76 | |
| -4.71 | |
| n/a | |
| -15.95 | |
| P/B (ttm) | 3.09 |
| P/S (ttm) | 402.81 |
| Earnings Date | Nov 9, 2026 |
| Ask | 67.84 |
| Volume | 894,604 |
| Avg. Volume (20D) | 1,580,193 |
| Open | 56.06 |
| Previous Close | 56.49 |
| Day's Range | 55.35 - 57.21 |
| 52-Week Range | 44.12 - 78.48 |
| Analyst | Buy |
| Price Target | 80 (43.39%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease area...
Financial Performance
In 2025, CRISPR Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 35M. Earnings were -581.6M, an increase of 58.8%.
Financial StatementsAnalyst Forecast
According to 18 analyst ratings, the average rating for CRSP stock is "Buy". The 12-month stock price forecast is 80, which is upside of 43.39% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $10M misses estimates by $0, with Infinity% YoY growth.
- EPS of -0.94 exceeds estimates by 0.24, with 27.13% YoY growth.
Analysts project revenue of ... Upgrade
